Modeling the long-term 2-8 °C stability profiles of a live, rotavirus vaccine candidate (RV3-BB) in various liquid formulations via extrapolations of real-time and accelerated stability data. (January 2022)

• Record Type: Journal Article
• Authors: Pullagurla, Swathi R.; Kumar, Prashant; Ogun, Oluwadara; Kumru, Ozan S.; Hamidi, Ahd; Hoeksema, Femke; Yallop, Christopher; Bines, Julie E.; Volkin, David B.; Joshi, Sangeeta B.
• Is Part Of: Biologicals. Volume 75(2022)
• Page Start: 21
• Page End: 28
• Publication Date: 2022-01
• Subjects: Rotavirus vaccine -- RV3-BB -- Formulation -- Stability -- Linear regression -- Arrhenius equation; Biological products -- Standards -- Periodicals; Biological Products -- Periodicals; Biological Products -- standards -- Periodicals; Produits biologiques -- Normes -- Périodiques; Biological products -- Standards; Periodicals; 615.37
• DOI: 10.1016/j.biologicals.2021.12.001
• Languages: English
• ISSNs: 1045-1056

Abstract

Abstract: To accelerate the formulation development of live-virus vaccine (LVV) candidates, more rapid approaches to rank-order formulations and estimate their real-time storage stability losses are needed. In this case-study, we utilize new and previously described stability data of a live, rotavirus vaccine candidate (RV3-BB) in three different liquid formulations to model and compare predicted vs. experimental RV3-BB stability profiles. Linear-regression extrapolations of limited real-time (2-8 °C) stability data and Arrhenius modeling of accelerated (15, 25, 37 °C) stability data provided predictions of RV3-BB real-time stability profiles (2-8 °C, 24 months). Good correlations of modeled versus experimental stability data to rank-order the RV3-BB formulations were achieved by employing (1) a high-throughput RT-qPCR assay to measure viral titers, (2) additional assay replicates and stability time-points, and (3) a −80 °C control for each formulation to benchmark results at each stability time-point and temperature. Instead of accumulating two-year, 2–8 °C storage stability data, the same rank-ordering of the three RV3-BB formulations could have been achieved by modeling 37°, 25°, 15° (and 2–8 °C) stability data over 1, 3 and 12 months, respectively. The results of this case-study are discussed in the context of accelerating LVV formulation development by expeditiously identifying stable formulations, estimating their shelf-lives, and determining vaccine vial monitoring (VVM) designations.